Efficacy and safety of 153 Sm-EDTMP as treatment of painful bone metastasis: a large single-center study

The purpose of this study is to assess the efficacy of Sm-EDTMP (Quadramet®) in a clinical setting. We have conducted a retrospective study of all consecutive patients (pts) treated with Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected:...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2018-03, Vol.26 (3), p.751
Main Authors: Kolesnikov-Gauthier, Hélène, Lemoine, Nathalie, Tresch-Bruneel, Emmanuelle, Olivier, Anaïs, Oudoux, Aurore, Penel, Nicolas
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Female
Humans
Male
Middle Aged
Pain - drug therapy
Radioisotopes - pharmacology
Radioisotopes - therapeutic use
Retrospective Studies
Samarium - pharmacology
Samarium - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study is to assess the efficacy of Sm-EDTMP (Quadramet®) in a clinical setting. We have conducted a retrospective study of all consecutive patients (pts) treated with Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters. Three hundred seventy consecutive Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases. Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
ISSN:1433-7339